USE OF MAILLARD REACTION INHIBITORS FOR THE TREATMENT OF AMYLOIDOSIS-BASED DISEASE

Abstract: Inhibitors of the Maillard reaction are useful in the treatment or prophylaxis of amyloidosis-based disease, particularly Alzheimer's disease. Particular examples include aminoguanidine and amphotericin B.

Description: USE OF MAILLARD REACTION INHIBITORS FOR THE TREATMENT OF AMYLOIDOSIS-BASED DISEASE This invention relates to preparations of use in the prophylaxis and treatment of amyloidosis -based diseases, including amyloid encephalopathies such as non-senile dementias , in particular Alzheimer' s disease. Alzheimer' s disease is a debilitating and eventually fatal disease of mature adults , typically in middle age. The causative agent is not yet understood, but it has similarities to other dementias, in particular scrapie in sheep and Creutzf eldt-Jakob and Gerstmann-Straussler-Scheinker syndromes and bovine spongiform encephalopathy (BSE) . These diseases are characterised by the histopathological features of neural amyloidogenesis. Particular examples are the paired helical filaments that form the neurofibrillar tangles in Alzheimer' s brains and the fibrils found in scrapie and other spongiform encephalopathies. These lesions are derived by modification of normal cellular proteins : tau in the case of Alzheimer' s and the prion protein ( PrP ) in the case of the spongiform encephalopathies. The nature of the modification remains unknown, but leads to amyloid plaques , neuronal degeneration and vacuolation, together with astroglial proliferation. Similarly, there is no known treatment for these diseases although it has been reported (You et al, Nature, 356, 598-601 (1992)) that the onset of scrapie is delayed in the present of the polyene antibiotic amphotericin B. We have discovered that amphotericin B unexpectedly acts as an inhibitor for the Maillard reaction. Furthermore we have shown that glycation of soluble tau from Alzheimer' s brains leads to the formation of amyloid filaments and that the Maillard reaction inhibitor a inoguanidine inhibits this aggregation. The Maillard reaction comprises the well known degradation of proteins in the"presence of reductive sugars such as glucose to form glycosylated proteins which are implicated in the complications of diabetes such as * cataract, nephropathy, retinopathy and atherosclerosis. Various classes of compounds are known to exhibit an inhibiting effect on the Maillard reaction and hence to be of use in the treatment or prophylaxis of the complications of diabetes and in diseases related to old age. Thus, for example, EP-A-0 433 679 describes 4-hydroxy-5, 8-dioxoquinoline derivatives of the following- formulae (a) a 4-hydroxy-5, 8-dioxoquinoline derivative of the formula (I) or a pharmaceutically acceptable salt thereof: wherein R. and R~ are each hydrogen, methyl, trifluoromethyl, carboxy, methoxycarbonyl or ethoxycarbonyl, and R_ is hydrogen or hydroxy; (b) a 4, 5, 8-trihydroxyquinoline derivative of the formula (II) or a pharmaceutically acceptable salt thereof: wherein R 1 , R_ and R, are as defined hereinbefore; (c) a 3-oxophenoxazine derivative of the formula (III) or a pharmaceutically acceptable salt thereof: wherein R. and R_ are each hydrogen or form by incorporation of C. and C_ carbon atoms a condensed [2, 1-b] pyridine ring optionally substituted with a hydroxyl group and/or a carboxyl group, and R β is hydrogen or hydroxy; or (d) a 3-oxophenoxazine N-oxide of the formula (IV) or a pharmaceutically acceptable salt thereof: (IV) wherein R4., R5 c and R6.. are as defined hereinbefore. EP-A-0 430 045 similarly discloses ascorbic acid tocopheryl phosphate diesters having Maillard reaction - inhibiting action, namely compounds of the formula: wherein R* , R_ and R_ independently of one another denote hydrogen or methyl, or a pharmaceutically acceptable salt thereof. Also EP-A-0 325 936 describes ami oguanidine derivatives of the general formula: 1 (wherein, R represents σarbocyσlic or heteroσylic ring substituted or unsubstituted by from 1 to 3 group (s ) selected from halogen atom, alkyl or alkoxy group of from 1 to 4 carbon atom(s ) , nitro group, phenoxy group, amino group, hydroxy group and acylamino group of from 2 to 4 carbon atom(s), X, represents single-bond, alk lene group of from 1 to 4 carbon atom(s) or alkenylene group of from 2 to 4 carbon atoms, or R together with X. represents alkyl group of from 1 to 4 carbon atom(s), R represents hydrogen atom, alkyl group of from 1 to 4 carbon atom(s) or phenyl group substituted or unsubstituted by from 1 to 3 group(s) selected from halogen atom, alkyl or alkoxy group of from 1 to 14 carbon atom(ε), hydroxy and nitro group), or an acid addition salt thereof. According to the present invention we provide the use of a pharmaceutically acceptable Maillard reaction inhibitor in the preparation of a pharmaceutical composition for the treatment or prophylaxis of amyloidosis-based disease, including amyloid encephalopathies such as non-senile dementias, in particular such disease in humans, especially Alzheimer' s disease. The invention also provides a method of treatment or prophylaxis of such diseases using the Maillard reaction inhibitors. The Maillard reaction inhibitors of use may comprise any of the various types mentioned above and also aminoglycosides such as amphotericin B and its analogues, as well as any other pharmaceutically acceptable product which can be shown to inhibit the Maillard reaction in a simple in vitro test. It is envisaged that the dosage rates of the active materials would be in the same range as those used in the treatment of other conditions, up to a maximum determined by the toxicity of the compound in question. The following description illustrates the Maillard-inhibitory effect of aminoguanidine and amphotericin B and the evidence for the implication of the Maillard reaction in Alzheimer' s paired helical filaments. E amυle 1 Soluble tau protein isolated from normal or Alzheimer' s brains was incubated for 24hr at 37 * C at a concentration of 1 mg/ml in lOmM reducing sugar solutions in 50mM phosphate buffer pH 6.8, ImM PMSF and 0. ImM GTP, in the presence or absence of the Maillard reaction inhibitor aminoguanidine. The formation of protein aggregates was analysed by electron microscopy by negative staining. Only soluble tau isolated from Alzheimer' s formed aggregates on glycation and this aggregation was inhibited by aminoguanidine. The aggregates formed on glycation by glucose resembled the amyloid fibrils seen in Alzheimer' s brains and the Maillard reaction inhibitor, aminoguanidine, inhibited the formation of these filamentous aggregates. Sugar Inhibitor Normal tau Alzheimer' s tau (25mM) ( lmg/ml) (lmg/ml) None No aggregates No aggregates Glucose No aggregates Filamentous aggregates Glucose aminoguanidine No aggregates No aggregates Fructose No aggregates Few aggregates Fructose aminoguanidine No aggregates No aggregates Example 2 Bovine serum albumin was dried from solutions containing reducing sugars and incubated at 55 * C for 3 weeks, in the presence or absence of various concentrations of either the Maillard reaction inhibitor aminoguanindine or the antibiotic amphotericin B. The extent of the Maillard reaction was quantified spectrophotometrically by the formation of brown colour. The results showed that the antibiotic amphotericin B, which had previously been shown to delay the onset of scrapie in an animal disease by an unknown mechanism, unexpectedly acted as a Maillard reaction inhibitor similar to aminoguanindine. Sugar Potential Ratio Absorbance (25mM) Inhibitor Sugar: Inhibitor extent of (molar basis) browning Glucose None 0.709 Glucose aminoguanidine 3: 1 0.603 Glucose aminoguanidine 2: 1 0.205 Glucose aminoguanidine 1: 1 0.212 Glucose aminoguanidine 1: 2 0.211 Glucose aminoguanidine 1: 3 0.154 None aminoguanidine 1: 3 0.186 Fructose None 2.5 Fructose aminoguanidine 1: 3 0.173 Glucose None 1: 3 0.999 Glucose amphotericin B 3: 1 0.548 Glucose amphotericin B 2: 1 0.349 Glucose amphotericin B 1: 1 0.258 Glucose amphotericin B 1: 2 0.235 Glucose amphotericin B 1: 3 0.206 None amphotericin B 0.205 Fructose None 2.347 Fructose amphotericin B 1: 3 0.224

Claims: AMENDED CLAIMS [received by the International Bureau on 20 September 1995 (20.09.95) original claims 1-3 replaced by amended claims 1-6 (1 page)] 1. The use of a pharmaceutically acceptable Maillard reaction inhibitor in the preparation of a pharmaceutical composition for the treatment or prophylaxis of amyloidosis-based disease. 2. Use according to claim 1, in which the Maillard reaction inhibitor comprises aminoguanidine. 3. Use according to claim 1, in which the Maillard reaction inhibitor comprises amphotericin B. 4 A method for the treatment or prophylaxis of amyloidosis-based disease comprising administration to a patient of an effective amount of a pharmaceutically acceptable Maillard reaction inhibitor. 5. A method according to claim 4, in which the Maillard reaction inhibitor comprises aminoguanidine. 6. A method according to claim 4, in which the Maillard reaction inhibitor comprises amphotericin B.

Inventors: COLACO CAMILO, ROSER BRUCE JOSEPH, COLACO, CAMILO, ROSER, BRUCE, JOSEPH
Applicants: COLACO CAMILO, QUADRANT HOLDINGS CAMBRIDGE, ROSER BRUCE JOSEPH, COLACO, CAMILO, QUADRANT HOLDINGS CAMBRIDGE LIMITED, ROSER, BRUCE, JOSEPH
Application year: 1995
Main classification: A61K31
IPC codes: A61K31, A61K45, A61P25, A61P43